 LEXINGTON, Mass., Nov. 10, 2020 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros or the Company Nasdaq: KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the third quarter of 2020. 